• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

    6/17/22 5:00:47 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRXP alert in real time by email
    SC 13D/A 1 sc13da113398002_06152022.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

    § 240.13d-2(a)

    (Amendment No. 1)1

    NRX Pharmaceuticals, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    629444 100

    (CUSIP Number)

    Jonathan C. Javitt

    c/o NRX Pharmaceuticals, Inc.

    1201 N. Market Street, Suite 111

    Wilmington, DE 19801

    (484) 254-6134

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    June 13, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 629444 100

      1   NAME OF REPORTING PERSON  
             
            Jonathan C. Javitt  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
               
      4   SOURCE OF FUNDS  
             
            PF, OO (see Item 3)  
      5   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)     ☐
           
               
      6   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   7   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         0  
    OWNED BY   8   SHARED VOTING POWER  
    EACH          
    REPORTING         14,868,329  
    PERSON WITH   9   SOLE DISPOSITIVE POWER  
             
              14,868,329  
        10   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            14,868,329  
      12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES     ☐
           
               
      13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
             
            22.3%  
      14   TYPE OF REPORTING PERSON  
             
            IN  

      

    2

    CUSIP No. 629444 100

    The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned (“Amendment No. 1”). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein.

    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    Item 6 is amended to add the following:

    Effective June 13, 2022, Jonathan Javitt Living Trust (“J. Javitt Living Trust”) entered into a Sales Plan (as amended on June 16, 2022, the “2022 Sales Plan”) with J.P. Morgan Securities LLC (“JPMS”) for the purpose of establishing a trading plan to effect sales of shares of Common Stock in compliance with all applicable laws, including, without limitation, Section 10(b) of the Exchange Act, and the rules and regulations promulgated thereunder, including, but not limited to, Rule 10b5-1. The 2022 Sales Plan allows for the sale of up to 2,000,000 of shares of Common Stock at certain prices above the closing price of the shares of Common Stock as of June 13, 2022 by JPMS on behalf of J. Javitt Living Trust, with a maximum of 1,000,000 shares to be sold in 2022 at a price of at least $2.50 and a maximum of 1,000,000 shares to be sold in 2023 at a higher minimum price. The 2022 Sales Plan does not contemplate the sale of securities prior to October 2022. The 2022 Sales Plan was entered into during the Issuer’s open trading window to allow for the possibility that the trustee of the J. Javitt Living Trust may be in possession of material nonpublic information during future open trading windows and, therefore, unable to implement a trading plan at such time.

    Shares of Common Stock sold pursuant to the 2020 Sales Plan Agreement may only be sold in accordance with trading parameters adopted by J. Javitt Living Trust, and there can be no assurance as to how many shares of Common Stock, if any, will be sold pursuant to the 2022 Sales Plan or at what price any such shares of Common Stock will be sold, subject to the applicable minimum trading parameters.

    3

    CUSIP No. 629444 100

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: June 17, 2022

     

    /s/ Jonathan C. Javitt

      Jonathan C. Javitt

    4

     

    Get the next $NRXP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXP

    DatePrice TargetRatingAnalyst
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $NRXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

    BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    4/2/25 8:51:11 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    12/18/24 8:27:36 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider B Group, Inc. claimed ownership of 3,000,000 shares (SEC Form 3)

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    8/21/25 6:21:37 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Abrams Michael S

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/11/25 5:00:05 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    12/18/24 8:27:36 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

    Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

    8/13/25 6:06:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

    WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

    8/11/25 4:05:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    SEC Filings

    View All

    NRX Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 4:31:21 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by NRX Pharmaceuticals Inc.

    424B5 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 8:01:41 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

    10-Q - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 6:07:13 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

    Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

    8/13/25 6:06:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

    WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

    8/11/25 4:05:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

    WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat

    7/29/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

    Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

    5/13/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

    WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

    1/15/25 8:02:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    9/13/22 4:47:33 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/17/22 5:00:47 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/22 3:59:15 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care